12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tozadenant: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 420 patients whose levodopa treatment was insufficient to control PD symptoms until their next dose showed that twice-daily oral tozadenant for 12 weeks met the primary endpoint of reducing mean daily "off" time in which patients experienced symptoms of their PD vs. placebo. Biotie said that tozadenant also met several secondary endpoints, including...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >